Skip to main content

Table 4 Discrimination, calibration and clinical utility measures of pathologic and pre-operative prediction models

From: Lymph node positivity in different early breast carcinoma phenotypes: a predictive model

 

Pathologic model

Pre-operative model

Probability of LN positivity

Criteria

Parametre

Initial set

Validation set

Initial set

Validation set

AUC

Est

0.754

0.767

0.681

0.687

 

95%CI

[0.742–0.765]

[0.75–0.783]

[0.668–0.693]

[0.669–0.705]

AUC (Bootstrap,

Est

0.755

0.766

0.682

0.686

B = 2000)

95%CI

[0.744–0.767]

[0.762–0.769]

[0.669–0.694]

[0.682–0.69]

Clinical utility

< 10%

19 (0%)

7 (0%)

1 (0%)

0 (0%)

10–20%

2255 (32%)

1096 (31%)

579 (7%)

279 (7%)

20–30%

1258 (18%)

586 (17%)

3137 (40%)

1487 (38%)

30–40%

1108 (16%)

559 (16%)

2478 (32%)

1315 (33%)

40–50

391 (5%)

188 (5%)

228 (3%)

125 (3%)

> = 50%

2102 (29%)

1076 (31%)

1429 (18%)

746 (19%)

Calibration

p-value

0.158

0.332

0.815

0.200

Probability of macrometastases

AUC (Delong)

Est

0.780

0.798

0.718

0.727

95%CI

[0.767–0.792]

[0.78–0.815]

[0.703–0.732]

[0.707–0.746]

AUC (Bootstrap,

Est

0.780

0.796

0.717

0.725

B = 2000)

95%CI

[0.767–0.793]

[0.793–0.799]

[0.703–0.732]

[0.721–0.728]

Clinical utility

< 10%

2029 (28%)

1004 (29%)

358 (5%)

184 (5%)

10–20%

2289 (32%)

1075 (31%)

5049 (64%)

2450 (62%)

20–30%

512 (7%)

262 (7%)

829 (11%)

465 (12%)

30–40%

726 (10%)

358 (10%)

307 (4%)

162 (4%)

40–50

644 (9%)

378 (11%)

573 (7%)

306 (8%)

> = 50%

933 (13%)

435 (12%)

736 (9%)

385 (10%)

Calibration

p-value

0.427

0.024

0.568

0.174